Santhera's Lack of FDA Support is not a Read Through for Sarepta Therapeutics (SRPT) - Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst, Michele Gilson reiterated her Outperform rating on Sarepta Therapeutics (NASDAQ: SRPT) after Santhera announced today that the FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE